Table 2.

Summary of incidence and severity of irAEs recorded in the study population

Toxicity	All irAEs (n = 83), n (%)	G1-2 irAEs (n = 65), n (%)	G3-4 irAEs (n = 18), n (%)
Skin toxicity	23 (27.7)	21 (32.3)	2 (11.1)
Rash	11 (13.3)	10 (15.4)	2 (11.1)
RCCEP	5 (6.0)	5 (7.7)	0 (0)
Psoriasis	3 (3.6)	3 (4.6)	0 (0)
Others	6 (7.2)	5 (7.7)	0 (0)
Pulmonary toxicity	20 (24.1)	14 (21.5)	6 (33.3)
Endocrine toxicity	15 (18.1)	14 (21.5)	1 (5.6)
Hypothyroidism	6 (7.2)	6 (9.2)	0 (0)
Hypoadrenocorticism	6 (7.2)	6 (9.2)	0 (0)
Diabetes	1 (1.2)	0 (0)	1 (5.6)
Hyperthyroidism	3 (3.6)	2 (3.1)	0 (0)
Cardiotoxicity	8 (9.6)	6 (9.2)	2 (11.1)
Digestive system toxicity	10 (12.0)	5 (7.7)	5 (27.8)
Gastrointestinal toxicity	1 (1.2)	0 (0)	1 (5.6)
Pancreatic toxicity	4 (4.8)	2 (3.1)	2 (11.1)
Hepatotoxicity	5 (6.0)	3 (4.6)	2 (11.1)
Bone and joint and muscle toxicity	4 (4.8)	3 (4.6)	1 (5.6)
Renal toxicity	2 (2.4)	2 (3.1)	0 (0)
Other	1 (1.2)	0 (0)	1 (5.6)

irAEs: immune-related adverse events; RCCEP: reactive cutaneous capillary endothelial proliferation;